Developing an effective HIV vaccine has been a challenge. The vaccine should naturally enhance the individual’s immunity against HIV infection and should be safe to use.

More than 16,000 adult volunteers were involved in the RV144 trial. Those receiving the HIV vaccine had 31 percent less chances of being infected with HIV as compared to those receiving placebo, but the reason for the effect was not known.
To understand this issue and to predict which people could possibly get infected, researchers analyzed the blood samples from a subset of participants: 41 of them were vaccinated but later became infected with HIV and 205 participants remain unaffected after vaccination.
The study found that those individuals in whom there was increased binding of the IgG immunoglobulin to a particular part of the HIV viral envelope called the first and second variable regions or V1V2 were well protected against HIV infection.
This binding might play a significant role in protecting the human cells from infection.
On the other hand, those individuals who showed a high binding of the IgA antibody to the first constant region or C1 region of the viral envelope showed less protection from the HIV virus. It was suggested that these antibodies may mitigate the protective effect of other protective antibodies.
Reference:
Source-Medindia
MEDINDIA




Email










